• Sab. Nov 23rd, 2024

Paclitaxel

  • Home
  • PEMBROLIZUMAB E TUMORE SENO TRIPLO NEGATIVO: -34% RISCHIO MORTE IN TERAPIA PRE E POST CHIRURGIA #ESMO24

PEMBROLIZUMAB E TUMORE SENO TRIPLO NEGATIVO: -34% RISCHIO MORTE IN TERAPIA PRE E POST CHIRURGIA #ESMO24

L’immunoterapia prima e dopo la chirurgia cambia la pratica clinica del tumore del seno triplo negativo. Lo dimostra la prima presentazione dei risultati di sopravvivenza globale (OS) dello studio di…

Long-term results from Testicular Cancer treatment are positive

A new study shows that by combining different chemotherapy drugs, testicular cancer remains highly treatable and often curable, even after first-line treatment fails. . The recent study published in the…